title: Lipoprotein(a) and apolipoprotein changes after cardiac transplantation.
abstract: Although lipoprotein changes after cardiac transplantation have been documented, the effects of transplantation and subsequent immunosuppressive therapy (particularly the combination of prednisone, azathioprine and cyclosporine) on apolipoprotein levels and lipoprotein(a) have not been reported. Fasting cholesterol, triglycerides, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, apolipoprotein A-1 and B-100 and lipoprotein(a) were evaluated in 69 consecutive patients during the waiting period before cardiac transplantation. There were 28 deaths before donor organ identification and 41 patients received a cardiac allograft. The lipoprotein levels of transplant recipients were again assayed 3 months postoperatively. Mean (+/- SEM) values increased for total plasma cholesterol (from 180 +/- 8 to 228 +/- 8 mg/dl, p less than or equal to 0.001), triglycerides (from 126 +/- 11 to 207 +/- 14 mg/dl; p less than or equal to 0.001), HDL cholesterol (from 39 +/- 2 to 49 +/- 3 mg/dl; p less than or equal to 0.002) and LDL cholesterol (from 119 +/- 7 to 138 +/- 7 mg/dl; p less than 0.02). Apolipoprotein A-1 and B-100 also increased, but lipoprotein(a) decreased from 11.7 +/- 1.7 to 6.8 +/- 1.1 mg/dl; p less than or equal to 0.0001) after transplantation. Although total cholesterol, triglycerides, LDL cholesterol, apolipoprotein A-1 and B-100 increased dramatically after cardiac transplantation, so did HDL cholesterol, thereby keeping the LDL/HDL cholesterol ratio constant. The surprising decrease in lipoprotein(a) after cardiac transplantation suggests that metabolism of lipoprotein(a) is independent of LDL cholesterol and that immunosuppressive drugs either decrease the synthesis or increase catabolism of lipoprotein(a).
authors.affiliation: Multi-Organ Transplant Center, Methodist Hospital, Houston, Texas.
authors.forename: J A
authors.initials: JA
authors.lastname: Farmer
authors.forename: C M
authors.initials: CM
authors.lastname: Ballantyne
authors.forename: O H
authors.initials: OH
authors.lastname: Frazier
authors.forename: B
authors.initials: B
authors.lastname: Radovancevic
authors.forename: C
authors.initials: C
authors.lastname: Payton-Ross
authors.forename: W
authors.initials: W
authors.lastname: Patsch
authors.forename: J D
authors.initials: JD
authors.lastname: Morrisett
authors.forename: A M
authors.initials: AM
authors.lastname: Gotto
authors.forename: J B
authors.initials: JB
authors.lastname: Young
mesh_terms: D001053:Apolipoproteins / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000453:epidemiology; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017270:Lipoprotein(a); D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D007166:Immunosuppressive Agents; D017270:Lipoprotein(a); D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol